Moderna May Be Just Getting Started in This Big Market
Moderna (NASDAQ: MRNA) generated billions of dollars in revenue and profit from its coronavirus vaccine over the past couple of years. The company leads the market along with rival Pfizer. But investors have worried about future revenue because right now, the coronavirus vaccine and booster are Moderna's only commercialized products.
The good news is that there's a big new market on the horizon. It won't bring in as much revenue all at once. But over time, it should be the source of recurrent blockbuster revenue. Moderna is ready to tackle this market this year -- and revenue should climb once it does. Let's find out more about this innovative biotech's next major opportunity.
That opportunity is the post-pandemic vaccine market. The idea is that part of the population will choose to go for annual coronavirus boosters -- just as they'd go for flu shots. In fact, Moderna compares the post-pandemic coronavirus vaccine market to that of the flu vaccine.
Source Fool.com
